Insights & methodology
Plain-language notes on cell-type-specific LNP delivery — written for wet-lab scientists choosing kits, designing experiments, or reading vendor copy critically. Every article cites primary sources.
How this site is built — every claim sourced, every datum graded
A short note on the discipline behind this site: every kit datum carries a source URL + evidence grade (A/B/C) + verified_at timestamp. What that means for buyers reading specs here vs reading marketing decks elsewhere.
CATP: a 525-fold IL-12 result, and what it means for SV-Delivery™ buyers
A 2025 peer-reviewed paper from Yingzhong Li and colleagues shows a 525-fold intratumoral IL-12 amplification using SunVax LNPs to co-deliver self-amplifying mRNA. Here is what to make of the result if you are a buyer of SV-Delivery™ kits.
Mouse cytokine results don't carry over: what Yingzhong's Q3 disclosure means for your experiment
In the Antibody Conference panel, Yingzhong Li disclosed that SunVax's current efficacy data uses mouse cytokine constructs — and that testing human cytokine constructs is the necessary next step. Here is what to do with that.
In vivo CAR-T: where lentivirus, AAV, and LNP each fit
In vivo CAR-T is a 5-10 year race between viral vectors and non-viral LNPs. Here is the landscape, in plain language, with the trade-offs that matter when picking a delivery kit today.
PDX is still mouse: reading the human in vivo evidence carefully
SunVax reports 92-94% efficacy in PDX models. PDX is patient-derived xenograft — the tumor cells are human, but the immune system and circulating environment are mouse. Here is how to interpret that.
Empirical screening, not ML, designs SV-Delivery™ kits
How SunVax explicitly chose an empirical-then-pattern workflow for LNP discovery, and why that matters for buyers reading "AI-driven" copy elsewhere.